Premium
Mesenchymal stem cells from the Wharton's jelly of umbilical cord segments provide stromal support for the maintenance of cord blood hematopoietic stem cells during long‐term ex vivo culture
Author(s) -
Bakhshi Tiki,
Zabriskie Ryan C.,
Bodie Shamanique,
Kidd Shan,
Ramin Susan,
Paganessi Laura A.,
Gregory Stephanie A.,
Fung Henry C.,
Christopherson Kent W.
Publication year - 2008
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2008.01926.x
Subject(s) - wharton's jelly , cord lining , mesenchymal stem cell , umbilical cord , cord blood , stem cell , haematopoiesis , cd34 , cd90 , ex vivo , bone marrow , immunology , cd44 , biology , adult stem cell , medicine , microbiology and biotechnology , cellular differentiation , cell , in vivo , biochemistry , gene , genetics
BACKGROUND: Hematopoietic stem cells (HSCs) are routinely obtained from marrow, mobilized peripheral blood, and umbilical cord blood. Mesenchymal stem cells (MSCs) are traditionally isolated from marrow. Bone marrow–derived MSCs (BM‐MSCs) have previously demonstrated their ability to act as a feeder layer in support of ex vivo cord blood expansion. However, the use of BM‐MSCs to support the growth, differentiation, and engraftment of cord blood may not be ideal for transplant purposes. Therefore, the potential of MSCs from a novel source, the Wharton's jelly of umbilical cords, to act as stromal support for the long‐term culture of cord blood HSC was evaluated. STUDY DESIGN AND METHODS: Umbilical cord–derived MSCs (UC‐MSCs) were cultured from the Wharton's jelly of umbilical cord segments. The UC‐MSCs were then profiled for expression of 12 cell surface receptors and tested for their ability to support cord blood HSCs in a long‐term culture‐initiating cell (LTC‐IC) assay. RESULTS: Upon culture, UC‐MSCs express a defined set of cell surface markers (CD29, CD44, CD73, CD90, CD105, CD166, and HLA‐A) and lack other markers (CD45, CD34, CD38, CD117, and HLA‐DR) similar to BM‐MSCs. Like BM‐MSCs, UC‐MSCs effectively support the growth of CD34+ cord blood cells in LTC‐IC assays. CONCLUSION: These data suggest the potential therapeutic application of Wharton's jelly–derived UC‐MSCs to provide stromal support structure for the long‐term culture of cord blood HSCs as well as the possibility of cotransplantation of genetically identical, HLA‐matched, or unmatched cord blood HSCs and UC‐MSCs in the setting of HSC transplantation.